Alzheimer's disease: on the verges of treatment and prevention

The Lancet Neurology

Volumn 8, Issue 1, 2009, Pages 4-5

  Burns, Alistair ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; CAD 106; DIMEBON; DONEPEZIL; GALANTAMINE; HOMOTAURINE; LY 2062430; MEMANTINE; PBT 2; PF 4360365; RIVASTIGMINE; TARENFLURBIL; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN METABOLISM; UNSPECIFIED SIDE EFFECT;

EID: 57149111902     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70271-0     Document Type: Note

References (8)

1. Holmes C., Boche D., Wilkinson D., et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
2. Elan, Wyeth present encouraging bapineuzumab phase 2 trial results at ICAD. http://www.medicalnewstoday.com/articles/116691.php (accessed November 9, 2008).
3. Lannfelt L., Blennow K., Zetterberg H., and on behalf of the PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7 (2008) 779-786
4. Wilcock G.K., Black S.E., Hendrix S.B., Zavitz K.H., Swabb E.A., Laughlin M.A., and on behalf of the Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7 (2008) 483-493
5. Sullivan M.G. Tramiprosate falls short in phase III Alzheimer's trial: unusually large placebo effect could be a recurring problem in studies that allow concomitant medications. http://www.entrepreneur.com/tradejournals/article/172316596.html (accessed November 9, 2008).
6. Doody R.S., Gavrilova S.I., Sano M., et al., on behalf of the Dimebon Investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (2008) 207-215
7. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
8. Peters R., Beckett N., Forette F., et al., for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 7 (2008) 683-689